Phenylpropanolamine


Concise Prescribing Info
Indications/Uses
Nasal congestion.
Dosage/Direction for Use
Adult : PO Per cap contains a combination w/ phenylpropanolamine HCl 18 mg: ≥13 yr 2 cap 4 hrly. Max: 8 cap/day. Per tab contains a combination w/ phenylpropanolamine HCl 25 mg: ≥13 yr 1 tab 4 hrly. Max: 4 tab/day.
Dosage Details
Oral
Nasal congestion
Adult: Per cap contains a combination w/ phenylpropanolamine HCl 18 mg: ≥13 yr 2 cap 4 hrly. Max: 8 cap/day. Per tab contains a combination w/ phenylpropanolamine HCl 25 mg: ≥13 yr 1 tab 4 hrly. Max: 4 tab/day.
Child: Per cap contains a combination w/ phenylpropanolamine HCl 18 mg: 6-12 yr 1 cap 4 hrly. Max: 4 cap/day. As oral liquid containing phenylpropanolamine 2.5 mg/5 mL: 6 mth-2 yr 2.5 mL tid, 3-5 yr 5 mL 3-4 times daily, 6-12 yr 5-10 mL 3-4 times daily.
Contraindications
Concurrent use or w/in 14 days after stopping MAOI.
Special Precautions
Hyperthyroidism, DM, ischaemic heart disease, HTN, renal impairment, closed-angle glaucoma. Patients who are overweight, or w/ eating disorders. May precipitate anginal pain in patients w/ angina pectoris. Elderly, pregnancy and lactation.
Adverse Reactions
HTN, headache, confusions, anxiety, dizziness, restlessness, insomnia, agitations, palpitations, tremors, blurred vision.
Potentially Fatal: Hypertensive crisis, haemorrhagic stroke.
Patient Counseling Information
May impair ability to drive or operate machinery.
Overdosage
Symptoms: Rapid pulse and respiration, disorientation, elevated BP, tachycardia, mydriasis, headache, CNS excitation, nausea, vomiting and anorexia. Management: Symptomatic and supportive treatment. Induced emesis and gastric lavage immediately.
Drug Interactions
Increased risk of HTN w/ indometacin. Increased risk of psychosis w/ amantadine.
Potentially Fatal: Increased risk of potentially fatal hypertensive crisis w/ or w/in 14 days after stopping MAOI. Increased risk of severe HTN and complications w/ bromocriptine.
Food Interaction
Further increased BP w/ caffeine.
Action
Description: Phenylpropanolamine is an indirect acting sympathomimetic, often used orally as the HCl salt for nasal congestion. It has been withdrawn in several countries due to increased risk of haemorrhagic strokes.
Pharmacokinetics:
Absorption: Readily and completely absorbed from GI tract. Time to peak plasma concentration: 1-2 hr.
Metabolism: Undergoes partial hepatic metabolism.
Excretion: Via urine 80-90% (unchanged). Half-life: Approx 3-5 hr.
Storage
Store below 25°C.
Disclaimer: This information is independently developed by MIMS based on Phenylpropanolamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in